KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Treasury Shares (2016 - 2018)

Historic Treasury Shares for BeOne Medicines (ONC) over the last 4 years, with Q4 2018 value amounting to $14.1 million.

  • BeOne Medicines' Treasury Shares rose 85971.48% to $14.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $14.1 million, marking a year-over-year increase of 85971.48%. This contributed to the annual value of $14.1 million for FY2018, which is 85971.48% up from last year.
  • BeOne Medicines' Treasury Shares amounted to $14.1 million in Q4 2018, which was up 85971.48% from $10.5 million recorded in Q2 2018.
  • Over the past 5 years, BeOne Medicines' Treasury Shares peaked at $14.1 million during Q4 2018, and registered a low of $44445.0 during Q4 2015.
  • In the last 4 years, BeOne Medicines' Treasury Shares had a median value of $1.5 million in 2017 and averaged $4.6 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first skyrocketed by 231871.98% in 2016, then surged by 3669.23% in 2017.
  • Quarter analysis of 4 years shows BeOne Medicines' Treasury Shares stood at $44445.0 in 2015, then soared by 2318.72% to $1.1 million in 2016, then soared by 36.69% to $1.5 million in 2017, then surged by 859.71% to $14.1 million in 2018.
  • Its last three reported values are $14.1 million in Q4 2018, $10.5 million for Q2 2018, and $4.1 million during Q1 2018.